Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02874430 · ClinicalTrials.gov registry record · Phase 2
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT02874430 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 29 participants.
The verdict
NCT02874430, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast or uterine cancer. Metformin hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Doxycycline may stop the growth of bacteria by keeping them from making proteins and minimized the toxic side effects of anti-cancer therapy. It is not yet known whether giving metformin hydrochloride together with doxycycline may be a better way in treating patients with localized breast or uterine cancer.
Interventions
- DRUG Metformin Hydrochloride
- DRUG Doxycycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-06-08 |
| Est. Completion | 2020-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02874430
The ClinicalTrials.gov registry entry for NCT02874430 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metformin Hydrochloride is the first listed.
NCT02874430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02874430 about?
NCT02874430 is a clinical study titled "Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer". This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast or uterine cancer. Metformin hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Doxycycline may stop the grow...
What is the current status of trial NCT02874430?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2016-06-08. Estimated completion is 2020-12-11.
What interventions are being tested in trial NCT02874430?
The interventions under investigation include: Metformin Hydrochloride (DRUG), Doxycycline (DRUG).
Who is sponsoring clinical trial NCT02874430?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.